Encapsulation of vitamin D3 using rhamnolipids-based nanostructured lipid carriers

This work had as main objective to encapsulate vitamin D3 (VD3) into nanostructured lipid carriers (NLCs) using rhamnolipids as surfactant. Glycerol monostearate and medium chain triglycerides with 2.625 % of VD3 were used as lipid materials. The three formulations of NLCs with VD3 (NLCs + VD3) were composed by 99 % of aqueous phase, 1 % of lipid phase and 0.05 % of surfactant. The difference between them was the ratio of solid: liquid in lipid phase. The NLCs + VD3 sizes ranged between 92.1 and 108.1 nm. The most stable formulation maintaining their caracteristics for 60 days at 4 degrees C. The NLCs + VD3 cytotoxicity demonstrated that concentrations of 0.25 mg/mL or lower up had a good biocompatibility in vitro. During the in vitro digestion, formulations with lower sizes and higher content on solid lipid had higher lipolysis rate and consequently higher VD3 bioaccessibility. The rhamnolipids-based NLCs are a good option for the encapsulation of VD3.

Automated summary

The main objective of this study was to encapsulate vitamin D3 (VD3) into nanostructured lipid carriers (NLCs) using rhamnolipids as surfactant. Glycerol monostearate and medium chain triglycerides with 2.625% of VD3 were used as lipid materials. The NLCs + VD3 formulations had sizes ranging from 92.1 to 108.1 nm and showed good stability for 60 days at 4 degrees C. Lower-sized formulations with higher solid lipid content exhibited higher lipolysis rate and VD3 bioaccessibility during in vitro digestion. Rhamnolipids-based NLCs are a promising option for VD3 encapsulation.